The goals and work of the European Research Initiative on CLL (ERIC)
Ibrutinib in combination with rituximab – the future of treating FL
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
From Structure to Function to Clinical Outcome
What leads to shorter progression-free survival in CLL patients?